A Plant-Produced Pfs25 VLP Malaria Vaccine Candidate Induces Persistent Transmission Blocking Antibodies against Plasmodium falciparum in Immunized Mice
| Autor: | Louis J. Casta, Valentina Mett, Robert W. Sauerwein, Jessica A. Chichester, Vidadi Yusibov, Moneim Shamloul, Stephen Tottey, Sandra K. Gibbs, Will Roeffen, Konstantin Musiychuk, Marga van de Vegte-Bolmer, Stephen J. Streatfield, Vadim Mett, Slobodanka D. Manceva, R. Mark Jones, Joey Norikane, Jennifer Jaje |
|---|---|
| Přispěvatelé: | Publica |
| Rok vydání: | 2013 |
| Předmět: |
viruses
Plasmodium falciparum Protozoan Proteins lcsh:Medicine Nicotiana benthamiana Antigens Protozoan complex mixtures law.invention Mice Antigen Poverty-related infectious diseases Infection and autoimmunity [N4i 3] law parasitic diseases Malaria Vaccines Tobacco mosaic virus Animals lcsh:Science Antibodies Blocking GeneralLiterature_REFERENCE(e.g. dictionaries encyclopedias glossaries) Multidisciplinary biology Malaria vaccine lcsh:R virus diseases biology.organism_classification Virology Recombinant Proteins Alfalfa mosaic virus biology.protein Recombinant DNA lcsh:Q Antibody Research Article |
| Zdroj: | PLoS ONE PLoS One, 8, 11 PLoS One, 8 PLoS ONE, Vol 8, Iss 11, p e79538 (2013) |
| ISSN: | 1932-6203 |
| Popis: | Malaria transmission blocking vaccines (TBVs) are considered an effective means to control and eventually eliminate malaria. The Pfs25 protein, expressed predominantly on the surface of the sexual and sporogonic stages of Plasmodium falciparum including gametes, zygotes and ookinetes, is one of the primary targets for TBV. It has been demonstrated that plants are an effective, highly scalable system for the production of recombinant proteins, including virus-like particles (VLPs). We engineered VLPs (Pfs25-CP VLP) comprising Pfs25 fused to the Alfalfa mosaic virus coat protein (CP) and produced these non-enveloped hybrid VLPs in Nicotiana benthamiana plants using a Tobacco mosaic virus-based 'launch' vector. Purified Pfs25-CP VLPs were highly consistent in size (19.3 +/- 2.4 nm in diameter) with an estimated 20-30% incorporation of Pfs25 onto the VLP surface. Immunization of mice with one or two doses of Pfs25-CP VLPs plus Alhydrogel (R) induced serum antibodies with complete transmission blocking activity through the 6 month study period. These results support the evaluation of Pfs25-CP VLP as a potential TBV candidate and the feasibility of the 'launch' vector technology for the production of VLP-based recombinant vaccines against infectious diseases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|